# RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

> **NCT06216938** · EARLY_PHASE1 · RECRUITING · sponsor: **Yana Najjar** · enrollment: 25 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Vusolimogene oderparepvec (RP1)

## Key facts

- **NCT ID:** NCT06216938
- **Lead sponsor:** Yana Najjar
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-07
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- Replimune, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06216938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06216938, "RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT06216938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*